GOLDRED NANOBIOTECH CO., LTD.
Update：2025/12/03
Industries
Main Industry
Consumer Goods
Main Product/Service
Golden Biotechnology Corporation is researching methods and compositions for treating RNA virus-induced diseases using cyclohexenone compounds. This aligns with their focus on developing novel therapeutic agents to address unmet medical needs, particularly in the realm of viral infections.
Founded Year
2011
Unified Business No.
53633736
Status
Active
Number of Employees
0
Total Paid-in
Capital
27,500,000 (NT$)
Location of Company
Taiwan
, Taoyuan City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Golden Biotechnology Corporation (GBC) is an Advanced Drug Development Company with an established Team that have a proven track record in Clinical Development, Regulatory Affairs & Commercialization.
GBC is focused on the clinical development of new therapeutic agents that can meet the needs of patients with of High Unmet Medical Needs.
Antroquinonol is an innovative compound discovered by the GBC Team with excellent Efficacy and Safety Profile. Antroquinonol have completed a number of Phase 1 and 2 studies in difficult to treat indications – Oncology and Infectious Diseases.
GBC’s looks excitedly to the future to solve the hardest questions on Antroquinonol to ultimately benefit patients and healthcare professionals.
GBC is focused on the clinical development of new therapeutic agents that can meet the needs of patients with of High Unmet Medical Needs.
Antroquinonol is an innovative compound discovered by the GBC Team with excellent Efficacy and Safety Profile. Antroquinonol have completed a number of Phase 1 and 2 studies in difficult to treat indications – Oncology and Infectious Diseases.
GBC’s looks excitedly to the future to solve the hardest questions on Antroquinonol to ultimately benefit patients and healthcare professionals.
